The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Blind prediction of response to erlotinib in early-stage non-small cell lung cancer (NSCLC) in a neoadjuvant setting based on kinase activity profiles.
R. Hilhorst
No relevant relationships to disclose
E. Schaake
No relevant relationships to disclose
R. van Pel
No relevant relationships to disclose
P. M. Nederlof
No relevant relationships to disclose
L. Houkes
No relevant relationships to disclose
M. Mommersteeg
No relevant relationships to disclose
R. de Wijn
No relevant relationships to disclose
M. van den Heuvel
No relevant relationships to disclose
P. Baas
No relevant relationships to disclose
R. Ruijtenbeek
No relevant relationships to disclose
H. M. Klomp
No relevant relationships to disclose